HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chronic obstructive pulmonary disease and β-blocker treatment in Asian patients with heart failure.

AbstractAIMS:
Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are increasingly frequent in Asia and commonly coexist in patients. However, the prevalence of COPD among Asian patients with HF and its impact on HF treatment are unclear.
METHODS AND RESULTS:
We compared clinical characteristics and treatment approaches between patients with or without a history of COPD, before and after 1:2 propensity matching (for age, sex, geographical region, income level, and ethnic group) in 5232 prospectively recruited patients with HF and reduced ejection fraction (HFrEF, <40%) from 11 Asian regions (Northeast Asia: South Korea, Japan, Taiwan, Hong Kong, and China; South Asia: India; Southeast Asia: Thailand, Malaysia, Philippines, Indonesia, and Singapore). Among the 5232 patients with HFrEF, a history of COPD was present in 8.3% (n = 434), with significant variation in geography (11.0% in Northeast Asia vs. 4.7% in South Asia), regional income level (9.7% in high income vs. 5.8% in low income), and ethnicity (17.0% in Filipinos vs. 5.2% in Indians) (all P < 0.05). Use of mineralocorticoid receptor antagonists and diuretics was similar between groups, while usage of all β-blockers was lower in the COPD group than in the non-COPD group in the overall (66.3% vs. 79.9%) and propensity-matched cohorts (66.3% vs. 81.7%) (all P < 0.05). A striking exception was the Japanese cohort in which β-blocker use was high in COPD and non-COPD patients (95.2% vs. 91.2%).
CONCLUSIONS:
The prevalence of COPD in HFrEF varied across Asia and was related to underuse of β-blockers, except in Japan.
AuthorsYoshiaki Kubota, Wan Ting Tay, Kuniya Asai, Koji Murai, Ikutaro Nakajima, Nobuhisa Hagiwara, Takanori Ikeda, Takashi Kurita, Tiew-Hwa Katherine Teng, Inder Anand, Carolyn S P Lam, Wataru Shimizu, ASIA-HF Study investigators
JournalESC heart failure (ESC Heart Fail) Vol. 5 Issue 2 Pg. 297-305 (04 2018) ISSN: 2055-5822 [Electronic] England
PMID29055972 (Publication Type: Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't)
Copyright© 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
Chemical References
  • Adrenergic beta-Antagonists
Topics
  • Adrenergic beta-Antagonists (therapeutic use)
  • Asia, Southeastern (epidemiology)
  • Comorbidity
  • Female
  • Follow-Up Studies
  • Heart Failure (drug therapy, epidemiology, physiopathology)
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Pulmonary Disease, Chronic Obstructive (drug therapy, epidemiology)
  • Stroke Volume (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: